Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMAG Pharmaceuticals Irons Out Ex-US Deal With Takeda For Feraheme

This article was originally published in PharmAsia News

Executive Summary

AMAG Pharmaceuticals announced April 1 it would team up with Takeda Pharmaceutical to commercialize its intravenous iron drug Feraheme (ferumoxytol) outside the US. A deal was not unexpected, as AMAG has signaled since winning approval from U.S. FDA in 2009 that the best way to maximize growth of Feraheme, especially in the European Union, is with a partner with global reach
Advertisement

Related Content

Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership
Takeda Continues Post-patent Prevacid Hit, Looks Externally For Innovation And Leadership
Nothing Anemic About Ferahame: The Med Helps Amag Exceeds Street Expectations
Ironing Out the Future: AMAG Hopes Its Novel Iron Therapy For CKD Wins Approval Next Week
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
3SBio And AMAG Ink Deal To Develop Ferumoxytol In China
Takeda's Global Ambition
Takeda's Global Ambition
2009 Medicare Budget Plan Pushes For ESA Bundling With Dialysis Rates
Advertisement
UsernamePublicRestriction

Register

SC074588

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel